Latest Videos |view all videos
Newly-diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years after diagnosis have essentially the same life expectancy as they did prior to diagnosis, a Mayo ...
Blacks may be twice as likely as whites to develop multiple myeloma because they are also more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance.
With the glut of data generated through next-generation sequencing, interpretation has become the new bottleneck in scientific discovery and clinical application.
A Mayo Clinic study reviewed data on more than 290,000 men with prostate cancer from the past 20 years and found that African-American men are at increased risk for poorer survival rate following prostate cancer treatment compared to other minority groups.
Unique laboratory testing during breast cancer lumpectomies to make sure surgeons removed all the cancerous tissue spares patients the need for a repeat operation in roughly 96 percent of cases at Mayo Clinic in Rochester.
A clinical trial co-led by Mayo Clinic Cancer Center researchers found that adding chemotherapy following radiation treatment improved survival for adults with low-grade gliomas by more than five years.
Needle-guided tumor destruction procedures offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology.
Mayo Clinic Researchers Help to Shine New Light on Bladder Cancer Tumors.
Mayo Clinic geriatric psychiatrist Maria Lapid, M.D., discusses a study developed by the Mayo Clinic Psycho-Oncology Research Group to improve quality of life of advanced cancer patients
Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer surgery leads to a greater risk for patients developing chronic kidney disease
The Prostate Cancer Medically Optimized Genome Enhanced Therapy Study (PROMOTE) aims to individualize treatments for men with castration-resistant prostate cancer.
Amir Lerman, MD, and Joerg Herrman, MD, discuss the emerging field of cardioncology that is developing as oncology patients live longer and possible treatment approaches.